MAPS AMERICAS DENVER 2026
MAPS Americas 2026 is underway in Denver — and the conversations happening this week are ones we’re paying close attention to. 1,500+ medical affairs professionals from biopharma and MedTech are gathered at the Hyatt Regency for sessions on the topics that matter most. Here are the ones that speak directly to the work we do […]
Intellus Worldwide 2026 Summit
🌎 Only 1 day left to the Intellus 2026 Summit – Clinakos is heading to Chicago. As the industry focuses on trends & disruptors, we are specifically looking forward to discussing how to: Prepare AI-ready datasets that move beyond traditional limitations. Transform the Insights Intelligence & Analytics function into a strategic co-pilot for the entire […]
Reuters Pharma USA 2026 kicks off in Philadelphia
Today, Reuters Pharma USA 2026 kicks off in Philadelphia. More than 1,500 senior pharma and biotech leaders — 87% Director level and above — are coming together for 2 days. Sessions will unpack the hardest problems in the industry across commercial strategy, market access, patient engagement, and AI at scale. With rare disease patients waiting […]
The Fraud Crisis in Patient Research
Every invalid patient record reshapes the science you depend on. In rare disease, that’s not a rounding error—it’s the dataset. 📊 Studies now report 10–15% fraud across general research and 15–25% in rare disease, with extremes hitting 94%. Small populations, high compensation, and invisible diagnostic trails make these frauds easy to miss—and devastating when overlooked. […]
Intellus Worldwide 2026 Summit Announcement Post
🌎 Clinakos is heading to the Intellus’ Worldwide 2026 Summit, the leading forum for healthcare insights, analytics, and evidence generation. From uncovering deep rare disease and oncology insights with Clarion™, to empowering advanced analytics teams with Acceleron™, to strengthening diagnosis verification through Confirmis™, we’re excited to share how our Medically Smart AI™ agents and Integrated […]
FDA’s focus on rare disease approvals
Half of FDA’s 2025 approvals targeted rare diseases. Real-world data made the difference.🧬 In 2025, rare diseases dominated the FDA approval portfolio: 26 of 46 novel drugs approved addressed rare or orphan disease indications. That’s consistent with a five-year trend—but this year was different. 📈 Why? The FDA’s Rare Disease Evidence Principles (RDEP) framework—introduced in […]
FDA’s 2026 PDUFA Calendar
📅 2026 FDA PDUFA Calendar Highlights a Pivotal Year for Rare Disease Innovation Beyond headline approvals, the FDA’s 2026 calendar underscores how far the rare disease pipeline has come—especially in cell and gene therapy. A number of key orphan drug decisions will shape the year ahead, reflecting the culmination of over a decade of translational […]
Understanding Rare Disease Patients
🔍 Understanding rare disease patients starts with seeing the full story behind every symptom, delay, and misdiagnosis—not just the ICD code. Why understanding rare disease patients matters 👥 Rare diseases collectively impact over 300 million people worldwide, yet each condition often affects only a small group of patients who are frequently overlooked. ⏳ Many patients […]
Importance of Data Privacy and Data Security
Patients, providers, and life sciences partners are all betting on the same thing: that the data connecting them is protected as carefully as any clinical intervention. 🧩 When that trust breaks—through a breach, outage, or misuse of data—the impact ripples across care delivery, research, and ultimately patient outcomes. 🔒 Security as a shared foundation For […]
AI Agents and Patient-Level Data – From Confirmation of Diagnosis to Insights
Join us on February 4, 2026, for an engaging discussion on how AI agents are transforming the way patient-level data is collected, validated, and turned into powerful insights. “AI Agents and Patient-Level Data – From Confirmation of Diagnosis to Insights” Presented by Wes Michael, President of Rare Patient Voice, and Inder Jaggi, CEO of Clinakos […]
